1. Scrip
  2. >>COVID-19

Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine

Follows Example Set By Sanofi

 
• By Kevin Grogan

In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.

baseball plate
Novartis steps up to COVID-19 VACCINE CHALLENGE • Source: Shutterstock

As concerns grow about supply failing to meet demand, Novartis AG has followed in the footsteps of Sanofi and agreed to help produce the COVID-19 vaccine developed by Pfizer Inc. and BioNTech SE.

The agreement will see Novartis use the aseptic manufacturing facilities at its site in Stein, Switzerland to take bulk mRNA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

In partnership with

Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development